PSYCHIATRY, INCLUDING PSYCHEDELIC, CLINICAL TRIALS SITE OPENS IN PRIMARY CARE SETTING Novel therapies drive demand for new Paratus Clinical site
With
Megan Morrison,
Chief Executive Officer, Paratus Clinical
Professor Paul Fitzgerald,
Principal Investigator, Paratus Clinical &
Head of School of Medicine and Psychology, Australian National University
Bernadette Fitzgibbon
Director of Psychiatry Research, Paratus Clinical &
Associate Professor, Australian National University
AUSTRALIAN HEALTH JOURNAL SEGMENT
Filmed in Melbourne | August 2025
Over the past decade, Paratus has been involved in over 200 clinical trials across 4 clinical site locations. Now a fifth site, the newly opened Melbourne site will cater to both primary care and psychiatry, specifically designed for psychedelic studies.
The new Melbourne site will be a focused on primary care studies specifically expanding access to psychiatric research, a growing area of unmet need. Australian Health Journal met with 3 recent hires brought in to support clinical trials across the organisation and in psychiatry in Melbourne.
– Megan Morrison, the recently appointed CEO of Paratus Clinical has 24 years of clinical research experience, industry knowledge and leadership, having worked across sponsor, CRO, and now site-side roles.
– Professor Paul Fitzgerald, the Director of the Australian National University School of Medicine and Psychology, provides senior academic leadership at Paratus Clinical as the Principal Investigator. Professor Fitzgerald is a renowned psychiatrist and researcher with over 25 years of experience leading clinical trials focused on psychiatric disorders. His pioneering work includes the development and evaluation of innovative treatments such as neurostimulation therapies (like transcranial magnetic stimulation) and novel pharmacological approaches. He plays a central role in trials in pharmacological-assisted psychotherapy and psychedelic compounds.
With extensive experience in conducting clinical research in psychiatry, Fitzgerald mentors the trial staff and ensures the integrity of the research protocols.
– Bernadette Fitzgibbon, the Director of Psychiatry Research at Paratus Clinical and Associate Professor at the Australian National University, has two decades experience in clinical research. She previously served as Deputy Director of the Monarch Research Institute and is affiliated with both Monash University and the Australian National University, contributing to national research efforts across psychiatry and psychology. She will collaborate closely with Professor Fitzgerald in running clinical trials in Melbourne.
Talking to Australian Health Journal, both Fitzgerald and Fitzgibbon highlight the growing need for innovative treatments in mental health, one which Paratus aims to address through a focused approach to psychiatric research.
Source: Adapted from transcript and Paratus Clinical news posts
You Might also like
-
Dental marketing insights from leading authority
Winning the Australian Dental Industry Award for Marketing has had a big impact to Dental Marketing Solutions. As Angus comments in closing, “Receiving the award is social proof to say, well, these guys must know something, because an independent body of their peers has assessed them and said”. He added, “Certainly it’s been good in terms of building our business.”
-
Getting the conversation going on the connection between oral health and chronic conditions
Dr. Carol Tran is an Oral Health Therapist and co-founder of Oral Health Home, an organisation focused on innovative, prevention-oriented oral health education and outreach. She is a Past President of Dental Hygienists Association of Australia (DHAA) and currently is the Scientific Program Chair, for upcoming congress in October 2025, for the newly formed Oral Health Association of Australia (OHAA).
-
Lasers in dental treatment without needles and drills
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.